EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS - Asset Resilience Ratio

Latest as of September 2025: 0.46%

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) has an Asset Resilience Ratio of 0.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EIS Eczacibasi Ilac Sinai ve Finansal Ya PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

TL322.48 Million
≈ $7.22 Million USD Cash + Short-term Investments

Total Assets

TL70.69 Billion
≈ $1.58 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2024)

This chart shows how EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's Asset Resilience Ratio has changed over time. See debt-free asset ratio of EIS Eczacibasi Ilac Sinai ve Finansal Ya to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EIS Eczacibasi Ilac Sinai ve Finansal Ya stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents TL0.00 0%
Short-term Investments TL322.48 Million 0.46%
Total Liquid Assets TL322.48 Million 0.46%

Asset Resilience Insights

  • Limited Liquidity: EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS maintains only 0.46% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Industry Peers by Asset Resilience Ratio

Compare EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Aurobindo Pharma Limited
NSE:AUROPHARMA
Drug Manufacturers - Specialty & Generic 1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Xeris Pharmaceuticals Inc
NASDAQ:XERS
Drug Manufacturers - Specialty & Generic 0.00%
Procter & Gamble Health Limited
NSE:PGHL
Drug Manufacturers - Specialty & Generic 33.01%

Annual Asset Resilience Ratio for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (2000–2024)

The table below shows the annual Asset Resilience Ratio data for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.53% TL298.71 Million
≈ $6.69 Million
TL56.20 Billion
≈ $1.26 Billion
+0.05pp
2023-12-31 0.48% TL303.65 Million
≈ $6.80 Million
TL62.80 Billion
≈ $1.41 Billion
-1.19pp
2022-12-31 1.67% TL388.04 Million
≈ $8.69 Million
TL23.23 Billion
≈ $520.33 Million
-0.35pp
2021-12-31 2.02% TL166.59 Million
≈ $3.73 Million
TL8.26 Billion
≈ $185.11 Million
+1.60pp
2020-12-31 0.42% TL25.07 Million
≈ $561.59K
TL5.97 Billion
≈ $133.72 Million
+0.39pp
2019-12-31 0.03% TL1.25 Million
≈ $28.09K
TL4.84 Billion
≈ $108.37 Million
+0.00pp
2018-12-31 0.03% TL1.15 Million
≈ $25.67K
TL4.46 Billion
≈ $99.81 Million
+0.02pp
2017-12-31 0.01% TL354.00K
≈ $7.93K
TL3.83 Billion
≈ $85.81 Million
-0.02pp
2016-12-31 0.03% TL1.08 Million
≈ $24.23K
TL3.99 Billion
≈ $89.43 Million
-0.03pp
2015-12-31 0.06% TL2.06 Million
≈ $46.25K
TL3.37 Billion
≈ $75.48 Million
+0.04pp
2014-12-31 0.02% TL763.00K
≈ $17.09K
TL3.26 Billion
≈ $73.09 Million
+0.01pp
2013-12-31 0.01% TL308.00K
≈ $6.90K
TL3.44 Billion
≈ $76.98 Million
0.00pp
2012-12-31 0.01% TL372.00K
≈ $8.33K
TL3.48 Billion
≈ $77.94 Million
-0.04pp
2011-12-31 0.05% TL1.40 Million
≈ $31.45K
TL3.03 Billion
≈ $67.90 Million
-0.08pp
2010-12-31 0.13% TL3.42 Million
≈ $76.58K
TL2.66 Billion
≈ $59.63 Million
-0.20pp
2009-12-31 0.33% TL8.17 Million
≈ $182.99K
TL2.49 Billion
≈ $55.75 Million
-0.40pp
2008-12-31 0.73% TL14.82 Million
≈ $332.04K
TL2.02 Billion
≈ $45.33 Million
-0.71pp
2005-12-31 1.44% TL18.77 Million
≈ $420.31K
TL1.30 Billion
≈ $29.14 Million
-2.00pp
2004-12-31 3.44% TL29.52 Million
≈ $661.13K
TL858.48 Million
≈ $19.23 Million
+3.44pp
2003-12-31 0.00% TL7.99 Billion
≈ $178.96 Million
TL739.70 Trillion
≈ $16.57 Trillion
-4.26pp
2002-12-31 4.26% TL11.19 Trillion
≈ $250.52 Billion
TL262.36 Trillion
≈ $5.88 Trillion
-0.48pp
2001-12-31 4.74% TL8.29 Trillion
≈ $185.77 Billion
TL174.96 Trillion
≈ $3.92 Trillion
-3.61pp
2000-12-31 8.35% TL10.58 Trillion
≈ $236.87 Billion
TL126.63 Trillion
≈ $2.84 Trillion
--
pp = percentage points

About EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

IS:ECILC Turkey Drug Manufacturers - Specialty & Generic
Market Cap
$1.30 Billion
TL58.18 Billion TRY
Market Cap Rank
#7952 Global
#59 in Turkey
Share Price
TL84.90
Change (1 day)
+1.07%
52-Week Range
TL40.40 - TL131.30
All Time High
TL131.30
About

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines. The Real Estate Development segment develops real estate properties; engages… Read more